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AutophagyCells rely on complementary proteolytic pathways including the ubiquitin–proteasome system and autophagy to
maintain proper protein degradation. There is known to be considerable interplay between them, whereby the
loss of one clearance system results in compensatory changes in other proteolytic pathways of the cell. Distur-
bances in proteolysis are known to occur in Alzheimer's disease, and potentially contribute to neurophysiological
and neurodegenerative processes. Currently, few data are available on how the presence of wild type andmutant
amyloid precursor protein (APPwt and APPmut) potentially alters the reciprocal interplay between the different
intracellular proteolytic pathways. This study used human SH-SY5Y neuronal cell lines, and SH-SY5Y transfected
with either APPwt or APPmut (valine-to-glycine substitution at position 717), in order to explore if the presence
of APPwt or APPmut altered the downstream effects of pharmacological proteasome or autophagy inhibition.
The occurrence of APPwt or APPmut was observed to disturb proteasome or autophagy activities upon treat-
ment with proteasome inhibitors or authophagy inhibitors. Interestingly, APPwt and APPmut expression was
observed to signiﬁcantly and robustly enhance the induction in cathepsin B following the administration of an
established proteasome inhibitor. The presence of APPwt and APPmut also signiﬁcantly reduced the elevation
in ubiquitinated proteins following proteasome inhibitor treatments. Our data strongly suggest that APP is able
to affect the downstreameffects of protease inhibition in neural cells including enhancement of cathepsin B activity,
with these changes in cathepsin B signiﬁcantly and inversely related to the levels of ubiquitinated protein.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Aging and awide variety of neurodegenerative conditions, including
Alzheimer's disease (AD), are characterized by alterations in the normal
cellular homeostasis with dysregulation of the proteostasis network.
Impairments in the functionality of proteolytic pathways favor the accu-
mulation of misfolded and abnormal proteins resulting in the deposi-
tion of toxic aggregates [1,2]. Cells possess two major intracellular
protein degradation systems namely the ubiquitin–proteasome system
(UPS) and autophagy. For several years they have been thought as
distinct and separated complexes whereas recently an increasing
number of data elucidated their intimate correlation [3–5]. The UPS
is the major degradation system used by cells to remove short-lived
andmisfolded proteins. TheUPS-mediated processing of proteins allowsmyloid-β; UPS, ubiquitin–pro-
-like; PGPH, peptidylglutamyl-
, branched-chain amino acids
mistry
ini).
ights reserved.the regulation of several cellular functions for example cell cycle
progression, DNA repair, apoptosis, gene transcription, signal transduc-
tion, senescence and immune response [6,7]. Autophagy or self-eating
is a lysosomal degradation pathway in charge of the recycling of dys-
functional organelles or aggregated proteins [8]. Different processes of
autophagy have been characterized based on the modality of cargo rec-
ognition and delivery to lysosomes: macroautophagy, microautophagy,
and chaperone-mediated autophagy (CMA) [8–11]. Only proteins can
be delivered to lysosomes via CMA, whereas both macroautophagy
and microautophagy concern the degradation of proteins and organ-
elles [10–15].
Alzheimer's disease, the most common form of neurodegenerative
condition, is characterized by intracellular and extracellular accumula-
tion of toxic protein aggregates. The deposition of these inclusions
further determines alterations in the functionality of the two clearance
systems with a general reorganization of the proteolysis. Additionally,
in vivo studies indicated that the accumulation of amyloid plaques, a
major hallmark of the pathology, can be inﬂuenced by both the UPS
system and the autophagy [16,17]. Plaques are a primary cause for pro-
teolysis inhibition in AD and are mainly constituted of amyloid-beta
peptides, Aβ(1–40) and Aβ(1–42). Both peptides derive from the
Fig. 1. Cell viability upon 24 h treatment with MG132 (5 μM) or 3MA (5 mM)was deter-
mined with the MTT assay performed as described in the Materials and methods section.
Results are expressed as percentage of viable cells compared to control untreated cells and
show a 30% decrease of viable cells in the presence of the proteasome inhibitor MG132
(n = 5).
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have revealed that mutant APP could favor AD development and pro-
gression regulating the generation of free radicals and oxidative damage
and causing structural alterations in mitochondria, with the production
of defective organelles and a decrease in mitochondrial trafﬁcking
[18–21]. Currently, little is known in terms of how the presence of
wild type or mutant forms of the amyloid precursor protein (APPwt
and APPmut, respectively) potentially alters the balance between the dif-
ferent intracellular proteolytic pathways.We recently demonstrated that
the expression of an APP mutant isoform correlates with an increase in
oxidative stress and a remodeled pattern of protein degradation, with
both marked inhibition of proteasome activities and impairment in the
autophagic ﬂux [3].
In the present work, we focused our attention on determining if
the presence of APPwt or APPmut altered the downstream effects of
proteasome/autophagy inhibition on protein ubiquitination and prote-
ase activity. On this purpose, human SH-SY5Y neuroblastoma cells stably
transfected with either wild-type APP gene (APPwt) or 717 valine-to-
glycine APP-mutated gene (APPmut) were used as experimental model.
Interestingly, we obtained that the presence of APPwt or APPmut is
able to inﬂuence the alterations in proteasome or autophagy activity
induced by the treatment with proteasome or authophagy inhibitors.
Additionally, APPwt or APPmut robustly enhanced the induction in
cathepsin B and, at the same time, signiﬁcantly reduced the elevation
in ubiquitinated proteins following the administration of an established
proteasome inhibitor.
2. Materials and methods
2.1. Reagents and chemicals
Substrates for assaying the chymotrypsin-like (ChT-L), trypsin-like
(T-L), peptidylglutamyl-peptide hydrolyzing (PGPH), aminopeptidase
N (AP-N) activities, proteasome inhibitors (Z-Gly-Pro-Phe-Leu-CHO,
lactacystin and MG132) and the autophagy inhibitor 3-methyladenine
(3MA) were purchased from Sigma-Aldrich S.r.L. (Milano, Italy). The
substrate Z-Gly-Pro-Ala-Leu-Ala-MCA to test the branched chain
amino acids preferring (BrAAP) activity was obtained by Biomatik
(Cambridge, Ontario). Aminopeptidase N (EC 3.4.11.2) for the coupled
assay utilized to detect BrAAP activity [22]was puriﬁed from pig kidney
as reported elsewhere [23]. SH-SY5Y transfected with APPwt or
APPmut gene were a kind gift of Prof. Uberti Daniela, University of
Brescia, Italy. Cathepsin B substrate, Z-Arg-Arg-AMC, and inhibitor,
CA074Me, were obtained from Sigma-Aldrich S.r.L. (Milano, Italy).
Cathepsin B antibody was purchased from Millipore (Billerica, MA).
All the other antibodies used in the present work were purchased
from Santa Cruz Biotech (Heidelberg, Germany). Media and chemicals
used for cell cultures were purchased from Euroclone (Milano, Italy).
Membranes forwestern blotting analyseswere purchased fromMillipore
(Milano, Italy). Proteins immobilized on ﬁlms were detected with the
enhanced chemiluminescence (ECL) system (Amersham Pharmacia
Biotech, Milano, Italy).
2.2. Cell treatment
Cell transfection was performed as previously reported [3]. Cells
were grown in 100-mm tissue culture dishes at an initial concentration
of 2 × 106 cells/dish and were exposed to MG132 (5 μM) or 3MA
(5 mM) for 24 h. After removing the medium and washing with cold
phosphate buffered saline (PBS), cells were harvested in 4 mL of PBS
and centrifuged at 1600×g for 5 min. The pellet was resuspended in a
lysis buffer (20 mM Tris, pH 7.4, 250 mM sucrose, 1 mM EDTA and
5 mM β-mercaptoethanol) and passed through a 29-gauge needle at
least ten times. Lysates were centrifuged at 12,000×g for 15 min and
the supernatants were stored at −80 °C. Protein concentration wasdetermined by the method of Bradford [24] using bovine serum albu-
min (BSA) as standard.
2.3. Cell viability assay
Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide assay (MTT) [25]. After experimental
treatment, MTT was added to the culture medium to a ﬁnal concentra-
tion of 0.5 mg/mL and incubated for 2 h at 37 °C. The medium was
replaced with 100 μL DMSO and the optical density was measured at
550 nm in a microtiter plate reader. At least six cultures were utilized
for each time point.
2.4. Western blotting
Cell lysates were then resolved by 12% SDS‐PAGE and electroblotted
onto PVDF membranes. Membranes with transferred proteins were in-
cubated with primary monoclonal antibodies and successively with
the speciﬁc peroxidase-conjugated secondary monoclonal antibodies
(Santa Cruz Biotech, Heidelberg). The immunoblot detection was
performed with an ECL western blotting analysis system. Each gel was
loaded with molecular weight markers, in the range 6.5 kDa to 205 kDa
(Sigma-Aldrich S.r.l., Milano, Italy). Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was utilized as control for equal protein
loading: membranes were stripped and re-probed for GAPDH using
a monoclonal antibody diluted 1:500. Bands were quantiﬁed as report-
ed elsewhere [26].
2.5. Measurements of proteasome activities in cell lysates
20S proteasome peptidase activities in cell lysates were determined
with ﬂuorogenic peptides: Suc-Leu-Leu-Val-Tyr-AMCwas used for ChT-
L activity, Z-Leu-Ser-Thr-Arg-AMC for T-L activity, Z-Leu-Leu-Glu-AMC
for PGPH activity, and Z-Gly-Pro-Ala-Leu-Ala-AMC for BrAAP activity.
The incubation mixture contained 1 μg of cell lysate, the appropriate
substrate and 50 mM Tris–HCl pH 8.0, up to a ﬁnal volume of 100 μL.
Incubation was performed at 37 °C, and after 60 min the ﬂuorescence
of the hydrolyzed 7-amino-4-methyl-coumarin (AMC) was detected
(AMC, λexc = 365 nm, λem = 449 nm) on a SpectraMax Gemini XPS
microplate reader. The 26S proteasome ChT-L activity was tested using
Suc-Leu-Leu-Val-Tyr-AMC as substrate and 50 mMTris–HCl pH 8.0 buff-
er containing 10 mMMgCl2, 1 mM dithiothreitol and 2 mM ATP. BrAAP
activity was determined in a coupled test in the presence of aminopepti-
dase N. The effective 20S proteasome contribution to short peptide cleav-
age was evaluated with control experiments performed using speciﬁc
proteasome inhibitors, Z-Gly-Pro-Phe-Leu-CHO and lactacystin (5 μM in
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of the values of control assays in the presence of the two inhibitors.
2.6. Measurements of cathepsin B activity in cell lysates
Cathepsin B proteolytic activity was measured following the proto-
col described by Tchoupè et al. [27] using the ﬂuorogenic peptide Z-
Arg-Arg-AMC at a ﬁnal concentration of 50 μM. Themixture, containing
1 μg of protein lysate, was incubated in 100 mM phosphate buffer
pH 6.0, 1 mM EDTA and 2 mM dithiothreitol for 1 h at 30 °C. The ﬂuo-
rescence of the hydrolyzed 7-amino-4-methyl-coumarin (AMC, λexc =
365 nm, λem = 449 nm) was detected on a SpectraMax Gemini
XPS microplate reader. The effective cathepsin contribution to theFig. 2. Panel I) T.U.N.E.L. and immunohistochemical results of control SH-SYSY, APPwt and APPm
by black-brownish nuclear stain. Violet stain indicates cathepsin B positive cells (red arrows)w
sin B positive cells and ubiquitin positive cells in the SH-SYSY line are observed (A). Higher level
sin B highest expression is observed inAPPmut line (C). 24 h incubationwithMG132 triggers the
strong cathepsin B staining inAPPmut cells is obtained afterMG132 treatment (F). 24 h incubati
ubiquitinated proteins (G, H, and I) (see text for further details). (IHC with Meyer's hematoxy
show the percentage of cathepsin B and ubiquitin positive cells calculated in each cell line with r
Methods section.proteolysis was evaluated through control experiments performed
using the speciﬁc inhibitor CA074Me. Fluorescence values obtained
by analyzing the lysates were then subtracted of the values of control
assays in the presence of the inhibitor.
2.7. Immunocytochemistry
For immunocytochemistry, cells were cultured in a Chamber Slide
system, and after 24 h of incubation with MG132 or 3MA, the mono-
layers were rapidly ﬁxed in a 50:50 mixture of methanol and acetone
for 5 min. In monolayers, apoptotic index was highlighted through a
TUNEL colorimetric staining (DeadEnd, Promega) according to theman-
ufacturer's instructions. For evaluation of the apoptotic rate, ten randomut cell lines after 24 h treatment withMG132 and 3MA. Apoptotic cells are characterized
hereas brown stain indicates ubiquitin positive cells (brown arrows). Low levels of cathep-
s of ubiquitin expression are detected in APPwt and APPmut cell lines (B–C), while cathep-
apoptotic pathway in the three cell lines (D, E and F) and enhances ubiquitin expression. A
onwith 3MA induces in the three cell lines similar low levels of apoptosis and a decrease in
lin nuclear counterstain; original magniﬁcation, 400. Bar = 25 μm.). Panel II) Bar graphs
espect to the speciﬁc untreated control. Data are analyzed as reported in the Materials and
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TUNEL-positive cells are characterized by a brownish-black nuclear
stain. For double-labeling immunocytochemistry, monolayers were ﬁrst
incubated with the anti-Ub antibody (1:50, Santa Cruz Biotech., Heidel-
berg, Germany); with the anti-cathepsin B antibody (1:100, Santa Cruz
Biotech., Heidelberg, Germany), and then with biotin-labeled goat
anti-rabbit (1:200, Jackson ImmunoResearch, West Grove, PA) second-
ary antibody. The binding of the antibody was detected with the
Elite kit (Vector Laboratories), and the immunoreaction was developed
using twodifferent chromogens: violet (VIP, Vector, BurlingameUK) for
cathepsin-B and brown (DAB, Vector) for ubiquitin stain. Lower-power
digitized images were acquired with a BX-60 microscope (Olympus,
Melville, NY) equipped with a DEI-470 digital camera (Optronics,
Goleta, CA). For scoring of immunohistochemical positive cells, stained
cells were calculated using the mentioned light microscope, a ×40
objective, a ×10 eyepiece, and a square eyepiece graticule (10×10
squares, with a total area of 62,500 μm2). Ten randomly selected sites
were chosen for each chamber and arithmetic means were calculated.
Results are expressed as % of IHC positive cells calculated with respect
to their own untreated control. For all parameters considered, cells onFig. 3. Proteasome activities in control SH-SY5Y, APPwt and APPmut cells upon 24 h exposure t
ChT-L, T-L, PGPH and BrAAP activitiesweremeasured in cell lysates as described in theMaterials
proteasomal system, with the ChT-L and T-L activities being themost inﬂuenced. This activation
proteasome activity (see text for further details). Results are presented as percentage of residual
values of control assays in the presence of speciﬁc inhibitors. Data points marked with an a
(*p b 0.05, **p N 0.01).the margins of the chamber were not considered for evaluation to avoid
inﬂation of positive cell numbers.
2.8. Statistical analysis
Results are expressed as mean values and standard deviation of
results obtained from ﬁve separate experiments. Statistical analysis
was performed with one way ANOVA, followed by the Bonferroni test
using Sigma-stat 3.1 software (SPSS, Chicago, IL, USA). p-Values b0.05
and b0.01 were considered to be signiﬁcant.
3. Results
Recent data from our laboratory and other groups evidenced as a
feature of neurodegenerative disorders the occurrence of an integration
between the twomain intracellular clearance systems, proteasome and
autophagy, suggesting for example the activation of compensatory
autophagy in the presence of proteasomal impairments [28–30]. In
this paper our goal is to better describe the interplay between the two
proteolytic pathways determining also if the presence of the APP wild-o the proteasome inhibitor MG132 (5 μM) and the autophagy inhibitor 3MA (5 mM). The
andMethods section. 3MAdetermines a clear and component-dependent activation of the
ismostly evident in SH-SY5Y cells. As expected,MG132 induces a considerable decrease in
activity toward the respective untreated control. Fluorescence unitswere subtracted of the
sterisk are statistically signiﬁcant compared to their respective non-treated control cells
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tionship. On this purpose we treated control SH-SY5Y, SH-SY5Y APPwt
and SH-SY5Y APPmut cells with a well-known proteasome inhibitor,
MG132 (5 μM ﬁnal concentration), and with 3MA (5 mM ﬁnal concen-
tration), an inhibitor of the autophagosome formation process [31,32],
for 24 h. Cells were ﬁrst tested for viability showing a 30% decrease of
viable cells in the presence of MG132 (Fig. 1). Immunocytochemical
analyses indicated an evident positivity to TUNEL staining, character-
ized by black-brownish nuclei, in the three cell lines upon exposure to
the proteasome inhibitor (Fig. 2), conﬁrming the ability of MG132 to
trigger the apoptotic pathway [33,34]. Enzymatic assays and western
blotting analyseswere then conducted in order tomonitor the function-
ality and expression levels of components of both pathways upon ex-
posure to the inhibitors. Inhibiting autophagy with 3MA produced a
clear and component-dependent activation of the proteasomal system
(Fig. 3). In particular, not transfected SH-SY5Y cells showed a 50% in-
crease of the ChT-L activity of the 20S proteasome. An evident increase
in the 20S ChT-L component was also observed in APPwt and APPmut
cells, with 3MA inducing a 40% and 25% increase, respectively. A similar
pattern was obtained measuring the ChT-L activity of the 26S protea-
some, a structure in charge of the degradation of polyubiquitinated sub-
strates resulted from the binding of the 19S regulatory particle to the
20S catalytic core. Also the T-L proteasomal component resulted particu-
larly enhanced in not transfected SH-SY5Y and APPwt cells with a 45%
and 30% increase, respectively, compared to the respective untreated
cells. It is interesting to note that in the presence of the mutant form of
APP the increase in proteasome activity is extremely limited. A possible
reason for this reduced activation is that basal activity levels of the UPS
system in APPmut cells are lower if compared to non-transfected cells
thus indicating the presence of a less efﬁcient and less reactive complex
[3]. The PGPH and BrAAP components only evidenced a slight increase
in the presence of the inhibitor and no differences due to the presence
of APPwt and APPmut were detected. The activation of the proteasomal
system in the presence of 3MA was conﬁrmed by western blottingFig. 4. Detection of the levels of ubiquitinated proteins and p27 in control SH-SY5Y, APPwt an
autophagy inhibitor 3MA (5 mM). In accordance to the data on proteasomal activities, in the t
details). Panels A and B show, respectively, representative immunoblots and densitometric ana
an anti-GAPDH antibody. The detection was executed by an ECL western blotting analysis sy
respective non treated control cells (*p b 0.05, **p b 0.01). (A.U.) arbitrary units.assays performedwith primary antibodies directed against ubiquitinated
proteins and p27, two established markers of proteasomal functionality.
Results shown in Fig. 4 evidence a decrease in the levels of both markers
upon 3MA treatment in the three cell lines, in agreement with the data
from the activity assays. As expected, the treatmentwith the proteasome
inhibitor MG132 induced a considerable decrease in proteasome activity
and accumulation of its substrates. Interestingly, following the adminis-
tration of the proteasome inhibitor, the presence of APPwt and APPmut
signiﬁcantly reduced the elevation in ubiquitinated proteins (Fig. 4).
Results obtained from immunocytochemical analyses were in agreement
with both evidences on ubiquitin data: in Fig. 2, in fact, panels D, E and F
show that 24 h incubation with MG132 was able to enhance ubiquitin
expression, with the highest levels detected in SH-SY5Y control cells,
whereas panels G, H, and I illustrate that the treatment with 3MA in-
duced a decrease in the levels of ubiquitinated proteins in the three
cell lineswhen compared to the respective untreated cells. Additionally,
IHC performed on untreated cells conﬁrmed our previous data on basal
proteasomal activity and ubiquitin intracellular levels [3]: as a result of
an inhibited proteasomal system, in fact, ubiquitinated proteins were
considerably higher in transfected cells compared to control SH-SY5Y
cells (Fig. 2 panels A, B and C).
We then investigated the way autophagy reacts to the induction
of proteasome inhibition. We analyzed the expression levels of three
known markers of the autophagic pathway: p62, LC3 and beclin-1.
The LC3 protein exists in cells in two forms, namely LC3-I (cytosolic)
and LC3-II (membrane-bound). When autophagy is activated, LC3-I is
processed and recruited into the autophagosome,where LC3-II is gener-
ated by site-speciﬁc proteolysis and lipidation near the C-terminus.
Similarly, beclin-1 is involved in the enrolment of membranes to form
autophagosomes, whereas p62 binds to both LC3-II and ubiquitin, and
is ﬁnally degraded in autophagolysosomes [35,36]. Results shown in
Fig. 5 clearly evidence an activation of the autophagic pathway in re-
sponse toMG132-induced proteasome inhibition. In detail, we obtained
a decrease in the amount of p62, whose levels inversely correlate withd APPmut cells upon 24 h exposure to the proteasome inhibitor MG132 (5 μM) and the
hree cell lines both markers result up-regulated upon 3MA treatment (see text for further
lyses obtained from ﬁve separate experiments. Equal protein loadingwas veriﬁed by using
stem. Data points marked with an asterisk are statistically signiﬁcant compared to their
Fig. 5. Detection of the autophagy-related proteins LC3-II, beclin-1 and p62 in control SH-SY5Y, APPwt and APPmut cells upon 24 h exposure to the proteasome inhibitor MG132 (5 μM)
and the autophagy inhibitor 3MA (5 mM). Results clearly evidence anactivation of the autophagic pathway in response toMG132with a decrease in the amount of p62 and a simultaneous
increase in the levels of both LC3-II and beclin-1 (see text for further details). Panels A and B show, respectively, representative immunoblots anddensitometric analyses obtained fromﬁve
separate experiments. Equal protein loading was veriﬁed by using an anti-GAPDH antibody. The detection was executed by an ECL western blotting analysis system. Data points marked
with an asterisk are statistically signiﬁcant compared to their respective non treated control cells (*p b 0.05, **p b 0.01). (A.U.) arbitrary units.
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beclin-1 that suggests an up-regulated formation of autophagosomes.
Recent ﬁndings similarly demonstrated adaptive changes in autophagy
after UPS impairment in Parkinson's disease where SH-SY5Y cells
treated with lactacystin showed a signiﬁcant increase in the expres-
sion levels of LC3-I/II and beclin-1 and reduced levels of p62 [28].
Changes in the autophagic pathway induced by MG132 were partic-
ularly evident in transfected cells, mainly in those with the APPmut
gene (Fig. 5).
We then tested if MG132 treatment induced some effect on
the activity of cathepsin B, a lysosomal cysteine protease of the papain
family, and if the presence of either APPwt or APPmut could inﬂuence
this effect. Interestingly, a remarkable activation of the enzyme was
observed when the proteasome was inhibited (Fig. 6). SH-SY5Y cells
showed a 2.4-fold increase of cathepsin B activity compared to the re-
spective untreated control. This increase was absolutely more evident
in APPwt and APPmut cells that showed a 5.45- and 6.4-fold enhance-
ment, respectively, compared to their own untreated control. As re-
vealed by the western blotting, MG132 induced in the three cell lines
an increased expression of mature cathepsin B, most likely responsible
for the described up-regulated activity. Immunocytochemical assay,
performed using an anti-cathepsin B antibody, detected a similar and
remarkable increase in cathepsin B expression upon MG132 exposure.
Panels E and F of Fig. 2, corresponding to APPwt andAPPmut cells treated
withMG132, show an intense violet stain corresponding to high levels ofcathepsin B. Treating with 3MA, an enhancement in the levels of the
enzyme was evident in control SH-SY5Y and APPwt cells (Fig. 2, panels
G and H). This increase can be addressed considering that the antibody
is able to bind both forms of cathepsin B, the proenzyme and themature
form. Conversely, in the western blotting experiment we were able to
separate through gel electrophoresis the two forms and only the active
form is shown (Fig. 6).
4. Discussion
The results shown in the present paper contribute to strengthen
the available data on the strict interdependence between the two
main intracellular proteolytic pathways, the UPS and autophagy [3,4],
and evidence a role for APP in altering the downstream effects of the in-
hibition of proteasome or autophagy on the activity of both pathways.
As for the ﬁrst point, we clearly demonstrated that the inhibition of
one system promotes a compensatory reaction of the other and that
this effect is bidirectional. In details, the inhibition of the autophagic
pathway, through the use of 3MA, determines an activation of the
proteasomal system, mainly evident for the ChT-L and T-L components,
and also conﬁrmed by the corresponding decreased expression of two
known proteasomal substrates, ubiquitinated proteins and p27. On
the other hand, blockingproteasome functionalitywithMG132 resulted
in a strong upregulation of autophagy, as revealed by the changes ob-
served in the levels of proteins of the autophagic cascade. It is therefore
Fig. 6. Cathepsin B functionality and cathepsin B expression levels in control SH-SY5Y,
APPwt and APPmut cells upon 24 h exposure to the proteasome inhibitor MG132
(5 μM) and the autophagy inhibitor 3MA (5 mM). A signiﬁcant activation of the enzyme,
mainly evident in APPwt and APPmut cells, is observed upon proteasome inhibitionwith a
corresponding increased expression of themature form of cathepsin B (see text for further
details). Panel A shows data on cathepsin B activitymeasured as described in theMaterials
and Methods section. Results are presented as percentage of residual activity toward the
respective untreated control. Fluorescence units were subtracted of the values of control
assays in the presence of a cathepsin B speciﬁc inhibitor. Panels B andC show, respectively,
a representative immunoblot related to cathepsin B expression and the corresponding den-
sitometric analyses obtained from ﬁve separate experiments. Equal protein loadingwas ver-
iﬁed by using an anti-GAPDH antibody. The detection was executed by an ECL western
blotting analysis system. Data points marked with an asterisk are statistically signiﬁcant
compared to their respective non treated control cells (*p b 0.05, **p b 0.01). (A.U.) arbi-
trary units.
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UPS are carefully orchestrated and integrated. A deep understanding of
themechanisms responsible for this integration could certainly be help-
ful especially in an attempt tomodulate one of the two systems for ther-
apeutic approaches. For example, considering the occurrence in AD of
serious autophagy and proteasome alterations with a progressive col-
lapse of the intracellular proteolysis [37], a strategy aimed at compen-
sating these dysfunctions could ameliorate pathological and cognitive
deﬁcits of AD.
Interestingly, the use of these particular cellular models allowed
us to establish that the observed downstream effects of proteasome/
autophagy inhibition on the activity of the two degradation systems
are altered by the presence of APPwt or APPmut. In fact, downregulating
the UPS, autophagy activation was more evident in APPmut cells, con-
versely, reducing autophagy, a higher enhancement of proteasomal
functionality was detected in SH-SY5Y non-transfected cells. However,
as previously reported by our group [3], basal levels of proteasomeactivity are higher in control neuronal cells, whereas cathepsin B basal
activity is upregulated in APPmut cells.
Furthermore, we reported that APPwt and APPmut expression
was able to robustly enhance the induction in cathepsin B and to signif-
icantly reduce the elevation in ubiquitinated proteins following the ad-
ministration of an established proteasome inhibitor. These data strongly
suggest a role for APP in the modulation of the downstream effects of
protease inhibition in neural cells including enhancement of cathepsin
B activity, with these changes in cathepsin B activity signiﬁcantly and
inversely related to the levels of ubiquitinated protein. The activation
of cathepsin B processing toward its mature form can be therefore con-
sidered a strategy of AD neurons to get rid of the ubiquitinated protein
overload induced byMG132 treatment. Additionally, considering that in
AD models, with or without familial mutations, cathepsin B was able
to reduce Aβ(1–42) levels, thus contrasting its accumulation and aggre-
gation [38,39], increasing its activity could offer a potential strategy in
the treatment of AD.
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